Mastodon

Canison® (Tablets, Solution, Cream) Instructions for Use

ATC Code

G01AF02 (Clotrimazole)

Active Substance

Clotrimazole (Rec.INN registered by WHO)

Clinical-Pharmacological Group

A drug with antifungal action for topical use in gynecology

Pharmacotherapeutic Group

Antifungal agent

Pharmacological Action

A broad-spectrum antifungal agent for vaginal use. The action of clotrimazole is associated with the disruption of ergosterol synthesis, which is a component of the fungal cell membrane, this alters the permeability of the cytoplasmic membrane and causes subsequent cell lysis.

In low concentrations, it acts fungistatically; in high concentrations, it acts fungicidally, and not only on proliferating cells. In fungicidal concentrations, it interacts with mitochondrial and peroxidase enzymes, resulting in an increase in the concentration of hydrogen peroxide to a toxic level, which also contributes to the destruction of fungal cells.

Clotrimazole exhibits fungicidal and fungistatic activity against dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis), yeast-like and mold fungi (Candida spp., including Candida albicans; Torulopsis glabrata, genus Rhodotorula, Pityrosporum orbiculare).

It is active against the causative agent of tinea versicolor – Pityrosporum orbiculare (Malassezia furfur). It is effective against gram-positive bacteria – the causative agent of erythrasma Corynebacterium minutissimum, as well as Staphylococcus spp., Streptococcus spp., gram-negative bacteria – Bacteroides, Gardnerella vaginalis. In high concentrations, it is active against Trichomonas vaginalis.

It does not affect lactobacilli. Primarily resistant variants of sensitive fungi are very rare; the development of secondary resistance in sensitive fungi is also noted in exceptional cases under therapeutic conditions.

Pharmacokinetics

When clotrimazole is applied intravaginally, absorption is 3-10% of the administered dose. High concentrations in vaginal secretion and low concentrations in the blood persist for 48-72 hours.

It is metabolized in the liver to inactive metabolites, which are excreted from the body by the kidneys and through the intestines.

Indications

Genital infections caused by yeast-like fungi of the genus Candida (candidal vulvovaginitis); sanitation of the birth canal before childbirth.

ICD codes

ICD-10 code Indication
B37.3 Candidiasis of vulva and vagina
N77.1 Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
1F23.10 Candidiasis of vulva and vagina
1F65 Enterobiasis
1H0Z Unspecified infection
QB9A Preparatory procedures for subsequent treatment
1A94.0 Genital or urogenital tract infection caused by Herpes simplex virus
GA41 Ulcerative or erosive diseases of vulva

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Solution, Cream

The dose, method, and regimen of administration are determined individually, depending on the indications, the patient’s age, and the dosage form used.

For external use, the duration of treatment depends on the severity of the disease, the localization of pathological changes, and the effectiveness of therapy.

It is necessary to strictly adhere to the correspondence between the indications and the dosage form used.

Tablets

The dose, method, and regimen of administration are determined individually, depending on the indications, the patient’s age, and the dosage form used.

For topical application, the recommended duration of therapy is 6 days.

It is necessary to strictly adhere to the correspondence between the indications and the dosage form used.

Adverse Reactions

Immune system disorders: allergic reactions, including urticaria, shortness of breath, arterial hypotension, fainting.

Gastrointestinal disorders frequency unknown – abdominal pain.

Renal and urinary disorders frequency unknown – frequent urination, intercurrent cystitis.

Reproductive system and breast disorders frequency unknown – itching, burning, hyperemia and swelling of the vaginal mucosa, ulceration of the vaginal mucosa, rash, pelvic pain, burning sensation in the penis of the sexual partner, pain during sexual intercourse.

Other frequency unknown – headache.

Contraindications

Hypersensitivity to clotrimazole; first trimester of pregnancy, menstruation period.

Use in Pregnancy and Lactation

Use is contraindicated in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus.

If it is necessary to use during lactation, the issue of discontinuing breastfeeding should be decided.

Use in Hepatic Impairment

In patients with hepatic insufficiency, the functional state of the liver should be periodically monitored.

Pediatric Use

It can be used in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the instructions for clotrimazole drugs regarding the use of specific dosage forms of clotrimazole in children of different ages and regarding contraindications for specific age groups in this category of patients.

Special Precautions

If allergic reactions or irritation occur at the site of application of the product, treatment should be discontinued.

To prevent reinfection, hygiene rules should be observed.

It is not recommended to apply clotrimazole to the skin in the eye area.

If clinical signs of infection persist after completion of treatment, a repeat microbiological examination should be performed to confirm the diagnosis.

To prevent infection/reinfection with genital infections, simultaneous treatment of sexual partners is necessary. During treatment, it is recommended to refrain from sexual intercourse.

When using dosage forms intended for topical intravaginal application, it is recommended to use reliable means of contraception. The risk of condom or diaphragm rupture increases with their simultaneous use with clotrimazole.

Drug Interactions

With simultaneous use with amphotericin B, nystatin, the activity of clotrimazole decreases.

Simultaneous intravaginal use of clotrimazole and oral tacrolimus, sirolimus may lead to an increase in the plasma concentration of the latter, so patients should be monitored for symptoms of overdose, if necessary, with measurement of plasma concentrations.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Agio Pharmaceuticals, Ltd. (India)

Dosage Form

Bottle OTC Icon Canison® Solution for external use 1%: fl. 20 ml

Dosage Form, Packaging, and Composition

Solution for external use transparent, colorless.

1 ml
Clotrimazole 10 mg

Excipients : propylene glycol – up to 1 ml.

20 ml – polyethylene bottles (1) – cardboard packs.

Marketing Authorization Holder

Agio Pharmaceuticals, Ltd. (India)

Dosage Form

Bottle OTC Icon Canison® Cream for external use 1%: bottle 20 ml

Dosage Form, Packaging, and Composition

Cream for external use 1% 1 g
Clotrimazole 10 mg

20 g – aluminum tubes (1) – cardboard packs.

Marketing Authorization Holder

Agio Pharmaceuticals, Ltd. (India)

Dosage Form

Bottle OTC Icon Canison® Vaginal tablets 100 mg: 6 pcs.

Dosage Form, Packaging, and Composition

Vaginal tablets 1 tab.
Clotrimazole 100 mg

Excipients : lactose monohydrate – 615 mg, corn starch – 226.6 mg, gelatin – 3.4 mg, magnesium stearate – 5 mg, microcrystalline cellulose – 25 mg, colloidal silicon dioxide – 15 mg, sodium propylparaben – 0.33 mg, sodium methylparaben – 1.67 mg, purified water – up to 992 mg.

6 pcs. – aluminum strips (1) complete with applicator – cardboard packs.

TABLE OF CONTENTS